OBI Pharma, Inc. is a Taiwanese pharmaceutical company with a medium risk ESG score of 24.4. Specializing in new drug research, OBI Pharma focuses on addressing challenging diseases like cancer, with a commitment to improving global health and quality of life. The company operates through four segments, including anti-cancer new drugs and bi-specific monoclonal antibodies, among others.